Savara Announces New Inducement Grants for 40,000 Shares to Bolster Team

Savara Inc. (SVRA) has announced new employment inducement grants to bolster its team. Two new employees received options for 20,000 shares and restricted stock units for another 20,000 shares, with an exercise price of $2.29 per share. The grants aim to incentivize new talent and support the company's rare respiratory disease treatments, including its flagship program MOLBREEVI* in Phase 3 development.

Savara Inc. (SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, has announced the grant of inducement awards to two new employees [1]. On July 15, 2025, the Compensation Committee of Savara's Board of Directors granted these inducement awards, which consist of options to purchase an aggregate of 20,000 shares of the Company’s common stock and restricted stock units (RSUs) covering an aggregate of 20,000 shares of the Company’s common stock [1]. The equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employees’ acceptance of employment with the Company [1].

The options have an exercise price of $2.29 per share, the closing trading price of the Company's common stock on the NASDAQ Global Market on the grant date. Each option has a 10-year term and vests as to 1/16th of the number of shares subject to the option on each quarterly anniversary of the employee’s first day of employment, subject to the employee’s continued employment on each such vesting date [1]. The RSUs vest in full on the two-year anniversary of the employee’s first day of employment, subject to the employee’s continued employment on such vesting date [1].

Savara’s lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH) [1]. The company aims to attract and retain top talent to support the advancement of its rare respiratory disease treatments.

References:
[1] https://www.businesswire.com/news/home/20250718610099/en/Savara-Announces-New-Employment-Inducement-Grant